Mammalian cationic proteins having lipopolysaccharide binding and anti-coagulant activity
US6103888A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jun 1, 1999 |
| Grant date | Aug 15, 2000 |
| Priority date | — |
| Expiry date | Jun 1, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/4723
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
Compositions and methods for the treatment and diagnosis of lipopolysaccharide-related conditions and coagulant-related disease are provided. Compositions include polypeptides which are identical or homologous to a certain cationic protein (CAP18) obtained from mammalian granulocytes, particularly including a reactive nitrogen inhibiting peptide (RNIP) fragment found at the carboxy-terminus of CAP18. Polypeptides are capable of binding to LPS and inhibiting LPS-mediated activation of macrophage, as well as interfering with the clotting cascade to inhibit coagulation in conditions such as disseminated intravascular coagulation. Compositions comprising the polypeptides in a suitable pharmaceutical carrier are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.